OCA
BIOA

Octagon Capital Advisors’s BioAge Labs BIOA Stock Holding History

Octagon Capital Advisors’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.8M Hold
1,748,000
– – 3.85% 8
2026
Q1 		$30.6M Buy
1,748,000
+150,000
+9% +$2.89M 3.38% 10
2025
Q4 		$21.1M Buy
+1,598,000
New +$14.2M 2.57% 15

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Octagon Capital Advisors's BIOA Position: Q2 2026 in Review

Octagon Capital Advisors held its BioAge Labs (BIOA) position steady in Q2 2026 at 1,748,000 shares worth $42.8M. The position accounts for 3.85% of the portfolio, ranked #8.

Octagon Capital Advisors first reported a position in BIOA in Q4 2025 and has held it in 3 quarters since. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Octagon Capital Advisors held 1,748,000 shares of BioAge Labs worth $42.8M as of Q2 2026.
  • Octagon Capital Advisors left its BioAge Labs share count unchanged in Q2 2026.
  • BioAge Labs made up 3.85% of Octagon Capital Advisors's portfolio in Q2 2026, its #8 holding.
  • Octagon Capital Advisors first reported a position in BioAge Labs in Q4 2025 and has held it in 3 quarters since.
  • 151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.